KEYTRUDA® (pembrolizumab) Plus Chemotherapy Considerably Improved Total Survival Versus Chemotherapy Alone as First-Line Therapy for Superior Malignant Pleural Mesothelioma
[ad_1] March 10, 2023 6:45 am ET RAHWAY, N.J. & KINGSTON, Ontario–(BUSINESS WIRE)– Merck (NYSE: MRK), referred to as MSD outdoors of the USA and Canada, and the Canadian Most cancers Trials Group (CCTG) at this time introduced that the Part 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 remedy, together with chemotherapy met its…